Senator Investment Group’s Novo Nordisk NVO Stock Holding History

Senator Investment Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-90,000	Closed	-$7.74M	–	68
2024 Q4	$7.74M	Sell	90,000 -10,000	-10%	-$1.08M	0.23%	53
2024 Q3	$11.9M	Sell	100,000 -45,000	-31%	-$6M	0.57%	50
2024 Q2	$20.7M	Sell	145,000 -5,000	-3%	-$663K	1.01%	39
2024 Q1	$19.3M	Buy	150,000 +140,000	+1,400%	+$16.7M	0.88%	37
2023 Q4	$1.03M	Buy	+10,000	New	+$989K	0.04%	62
2023 Q2	–	Sell	-850,000	Closed	-$67.6M	–	61
2023 Q1	$67.6M	Buy	850,000 +450,000	+113%	+$31.9M	3.69%	10
2022 Q4	$27.1M	Buy	+400,000	New	+$23.5M	2.44%	12

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Senator Investment Group's NVO Position: Q1 2025 in Review

Senator Investment Group sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 90,000 shares — an estimated $7.74M sold.

Senator Investment Group first reported a position in NVO in Q4 2022 and held it in 7 quarters. The position peaked at $67.6M in Q1 2023. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

Senator Investment Group reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
Senator Investment Group sold 90,000 Novo Nordisk shares in Q1 2025, an estimated $7.74M.
Senator Investment Group first reported a position in Novo Nordisk in Q4 2022 and held it in 7 quarters.
Senator Investment Group's Novo Nordisk position peaked at $67.6M in Q1 2023.
1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Senator Investment Group's 13F filing for Q1 2025, filed 14 May 2025.